ET Management Question 3
Transcript
The correct answer is hydroxyurea resistance reflects inadequate disease control despite adequate exposure, whereas intolerance reflects treatment-limiting toxicity. In essence, resistance is when the platelet count is poorly controlled, of at least 3 months of therapy with at least 2 grams per day of hydroxyurea, while having trouble balancing leukopenia or anemia. This can happen in around 15% to 20% of patients with hydroxyurea. So, difficulty controlling the platelet count while not incurring leukopenia or anemia with hydroxyurea would be one form of resistance. We also see issues surrounding non-hematologic toxicities like mucocutaneous mouth ulcers, or even worse, lower extremity medial malleolar ulcerations, which is a clear indication to stop hydroxyurea, or even Hydrea-related fevers or GI complaints.
So, one needs to be aware of the potential for intolerance at any dose, at any time period, but there are definitions set forth by the ELN that recognize poor control of the platelets or controlling the platelets at the expense of incurring leukopenia or anemia. These definitions matter because patients who have intolerance—who have resistance, rather—may not have a good outcome with hydroxyurea. So, it should prompt physicians and patients alike to consider alternative therapies.
References
- Tefferi A, Gangat N, Loscocco GG, et al. Essential thrombocythemia: a review. JAMA. 2025;333(8):701. doi:10.1001/jama.2024.25349
- Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024;99(4):697-718. doi:10.1002/ajh.27216
- Godfrey AL, Green AC, Harrison CN. Essential thrombocythemia: challenges in clinical practice and future prospects. Blood. 2023;141(16):1943-1953. doi:10.1182/blood.2022017625
- Sever M, Newberry KJ, Verstovsek S. Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea. Leuk Lymphoma. 2014;55(12):2685-2690. doi:10.3109/10428194.2014.893310
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myeloproliferative Neoplasms V.3.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed October 15, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
- Mesa R, Gill H, Zhang L, et al. Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS-ET): a multicentre, open-label, randomised, active-controlled, phase 3 study. Lancet Haematol. 2025;12(11):e862-e875. doi:10.1016/S2352-3026(25)00264-9
- Awada H, Voso M, Guglielmelli P, Gurnari C. Essential thrombocythemia and acquired von Willebrand syndrome: the shadowlands between thrombosis and bleeding. Cancers. 2020;12(7):1746. doi:10.3390/cancers1207174
- Park YH, Lee S, Mun Y, Park DJ. Prognostic value of modified criteria for hydroxyurea resistance or intolerance in patients with high‐risk essential thrombocythemia. Cancer Med. 2023;12(7):8073-8082. doi:10.1002/cam4.5602
- Reilly JT, McMullin MF, Beer PA, et al. Guideline for the diagnosis and management of myelofibrosis. Br J Haematol. 2012;158(4):453-471. doi:10.1111/j.1365-2141.2012.09179.x
- Tremblay D. Cytoreduction for ET and PV: who, what, when, and how? Hematol Am Soc Hematol. 2023;2023(1):660-666. doi:10.1182/hematology.2023000451
- Abu-Zeinah G, Hobbs GS, Rampal RK, et al. Molecular response, event-free survival, and treatment-free remission in myeloproliferative neoplasms: update and review with insights from MPN Asia 2026. Curr Hematol Malig Rep. 2026;21(1):21. doi:10.1007/s11899-026-00790-5
This presentation is funded by PharmaEssentia.
©2026 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.


